The binding energy values of ATP, ALK inhibitors and ABT-199 to ALK were obtained from AlphaFold and modeled protein structures. by Richard Junior Zapata Dongo (17912565)

Subjects:

Amino acids interactions and binding energy describe that ABT-199 binds to ALK^Mutant. by Richard Junior Zapata Dongo (17912565)

Subjects:

Western blot analysis of drug combinations. by Richard Junior Zapata Dongo (17912565)

Subjects:

ALKL1196M –ABT199 interactions. by Richard Junior Zapata Dongo (17912565)

Subjects:

ALK^wt–ABT199 interactions. by Richard Junior Zapata Dongo (17912565)

Subjects:

BCL2 protein keeps their expression in different conditions treatment nevertheless each EML4-ALK cell modells exhibit variable expression. by Richard Junior Zapata Dongo (17912565)

Subjects:

ALK inhibitors (Positive control) and ABT199 (Proposed binding) in complex with the ALK active side. by Richard Junior Zapata Dongo (17912565)

Subjects:

BCL2 antiapoptotic protein exhibits heterogeneous expression in Ba/F3 EML4-ALK^mutants. by Richard Junior Zapata Dongo (17912565)

Subjects:

Loewe synergy-antagonism score analysis shows additive and synergistic effects after ALKi and ABT-199 combination treatment. by Richard Junior Zapata Dongo (17912565)

Subjects:

Negative (Prednisone) and basal (ATP) control compounds binding to ALK protein. by Richard Junior Zapata Dongo (17912565)

Subjects:

Data Sheet 1_IGFBP5 mediates the therapeutic effect of isoliquiritigenin in myocardial ischemia-reperfusion injury via AKT/GLUT4 regulated insulin resistance.docx by Jue Bai (21195479)

“…</p>Propose<p>In this study, we aimed to investigate ISL’s therapeutic effects on MIRI. Moreover, we elucidate the underlying mechanisms of ISL regulated myocardium insulin resistance in vivo and in vitro.…”

Figure 4 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells by Zachary A. Schaaf (12912100)

Image 6_Tumor-associated bacteria activate PRDX1-driven glycolysis to promote immune evasion and PD-1 antibody resistance in hepatocellular carcinoma.jpeg by Heng Zhang (320479)

“…Background<p>Recent studies have highlighted the presence of intratumoral bacteria in hepatocellular carcinoma (HCC), yet their contribution to immunotherapy resistance remains largely unexplored. This study investigates the mechanisms by which bacterial infection reshapes tumor metabolism to undermine the efficacy of anti-PD-1 therapy.…”

Image 5_Tumor-associated bacteria activate PRDX1-driven glycolysis to promote immune evasion and PD-1 antibody resistance in hepatocellular carcinoma.jpeg by Heng Zhang (320479)

“…Background<p>Recent studies have highlighted the presence of intratumoral bacteria in hepatocellular carcinoma (HCC), yet their contribution to immunotherapy resistance remains largely unexplored. This study investigates the mechanisms by which bacterial infection reshapes tumor metabolism to undermine the efficacy of anti-PD-1 therapy.…”

Image 1_Tumor-associated bacteria activate PRDX1-driven glycolysis to promote immune evasion and PD-1 antibody resistance in hepatocellular carcinoma.jpeg by Heng Zhang (320479)

“…Background<p>Recent studies have highlighted the presence of intratumoral bacteria in hepatocellular carcinoma (HCC), yet their contribution to immunotherapy resistance remains largely unexplored. This study investigates the mechanisms by which bacterial infection reshapes tumor metabolism to undermine the efficacy of anti-PD-1 therapy.…”

Image 4_Tumor-associated bacteria activate PRDX1-driven glycolysis to promote immune evasion and PD-1 antibody resistance in hepatocellular carcinoma.jpeg by Heng Zhang (320479)

“…Background<p>Recent studies have highlighted the presence of intratumoral bacteria in hepatocellular carcinoma (HCC), yet their contribution to immunotherapy resistance remains largely unexplored. This study investigates the mechanisms by which bacterial infection reshapes tumor metabolism to undermine the efficacy of anti-PD-1 therapy.…”

Image 7_Tumor-associated bacteria activate PRDX1-driven glycolysis to promote immune evasion and PD-1 antibody resistance in hepatocellular carcinoma.jpeg by Heng Zhang (320479)

“…Background<p>Recent studies have highlighted the presence of intratumoral bacteria in hepatocellular carcinoma (HCC), yet their contribution to immunotherapy resistance remains largely unexplored. This study investigates the mechanisms by which bacterial infection reshapes tumor metabolism to undermine the efficacy of anti-PD-1 therapy.…”

Data Sheet 1_Tumor-associated bacteria activate PRDX1-driven glycolysis to promote immune evasion and PD-1 antibody resistance in hepatocellular carcinoma.docx by Heng Zhang (320479)

“…Background<p>Recent studies have highlighted the presence of intratumoral bacteria in hepatocellular carcinoma (HCC), yet their contribution to immunotherapy resistance remains largely unexplored. This study investigates the mechanisms by which bacterial infection reshapes tumor metabolism to undermine the efficacy of anti-PD-1 therapy.…”

Image 2_Tumor-associated bacteria activate PRDX1-driven glycolysis to promote immune evasion and PD-1 antibody resistance in hepatocellular carcinoma.jpeg by Heng Zhang (320479)

“…Background<p>Recent studies have highlighted the presence of intratumoral bacteria in hepatocellular carcinoma (HCC), yet their contribution to immunotherapy resistance remains largely unexplored. This study investigates the mechanisms by which bacterial infection reshapes tumor metabolism to undermine the efficacy of anti-PD-1 therapy.…”

Data Sheet 2_Tumor-associated bacteria activate PRDX1-driven glycolysis to promote immune evasion and PD-1 antibody resistance in hepatocellular carcinoma.docx by Heng Zhang (320479)

“…Background<p>Recent studies have highlighted the presence of intratumoral bacteria in hepatocellular carcinoma (HCC), yet their contribution to immunotherapy resistance remains largely unexplored. This study investigates the mechanisms by which bacterial infection reshapes tumor metabolism to undermine the efficacy of anti-PD-1 therapy.…”